Merrimack Pharmaceuticals (MACK) has its tail in the air after "encouraging clinical data" from the expanded Phase 1 study of MM-302 for treatment of advanced HER2-positive breast cancer.
"Patients treated with MM-302 showed no signs of clinical decline in cardiac function ... These results are encouraging for the development of our nanoliposomal technology platform, and an important step towards successfully establishing the safety and activity profile of MM-302 in the HER2-positive breast cancer population."
A Phase 2 study is being planned.
Shares +6% premarket